Diplomat Pharmacy (DPLO) Tops Q4 EPS by 2c; Issues Strong FY15 EPS Outlook

Diplomat Pharmacy (NYSE: DPLO) reported Q4 EPS of $0.08, $0.02 better than the analyst estimate of $0.06. Revenue for the quarter came in at $612 million versus the consensus estimate of $603.7 million.

Diplomat Pharmacy sees FY2015 EPS of $0.47-$0.50, versus the consensus of $0.42.

For earnings history and earnings-related data on Diplomat Pharmacy (DPLO) click here.

You May Also Be Interested In

• Ondas Holdings Inc. (ONDS) Misses Q2 EPS by 9c
• Aebi Schmidt Holding AG (AEBI) Reports Q2 results; offers guidance
• Bending Spoons S.p.A. (BSP) Tops Q2 EPS by 19c; offers guidance